Pre-market Hot Trades in US Stocks

Nektar Therapeutics is up 7.40% in pre-market trading. Based on recent important news:

1. On July 21, analysts set a consensus target price of $14.57 for Nektar Therapeutics, indicating a 33% upside potential, although analysts may be considering the long-term nature of clinical trials.

2. On July 21, short interest decreased by over 30%, typically indicating a weakening of bearish sentiment.

3. On July 21, market analysts did not include Verve Therapeutics in their recommended list, suggesting that Nektar Therapeutics may be more attractive.

Top Gainers in Pre-market US Stocks

Dongfang Sheng is up 55.80% in pre-market trading. Based on recent important news:

1. On July 22, Dongfang Sheng announced the pricing of its public offering at $0.4681 per unit, planning to raise approximately $6.9 million. This news led to a pre-market drop of 60% in stock price.

2. On July 22, the market reacted positively to Dongfang Sheng's fundraising plan, resulting in a significant rebound in pre-market stock price.

3. On July 21, there was increased attention on the US and Chinese stock markets, with rising investor interest in the Chinese market.

Garden Stage is up 54.37% in pre-market trading. Based on recent important news:

1. On June 19, Garden Stage Ltd announced a self-underwritten issuance of 6.1 million common shares directly to specific investors, causing significant stock price volatility.

2. On June 16, there was increased market attention on AI applications, driving related sectors up and indirectly affecting Garden Stage's market performance.

3. On June 9, overheated domestic market sentiment led to irrational stock price fluctuations, impacting Garden Stage's trading activity.

Incannex Healthcare is up 38.61% in pre-market trading. Based on recent important news:

1. On June 17, Incannex Healthcare formed a joint venture with Mind Medicine Australia to expand access to psychedelic-assisted therapies, driving stock price up.

2. On May 29, Incannex Healthcare received FDA approval to advance the IHL-42X trial to Phase 3, resulting in a stock price increase.

3. On May 28, the company increased its available shares to $50 million through a revised sales agreement, boosting market confidence